Hints and tips:
Related Special Reports
...His marriages to actress Mary Beth Hurt and artistic director Heidi Henderson each ended in divorce. He had four children....
...Rivals AstraZeneca, Johnson & Johnson, Russia’s Sputnik V and new entrants such as Novavax make up the remainder of the market, which is forecast to double in value to $124bn next year....
...“Africa is a key market for Sputnik V,” said the Russian Direct Investment Fund, a Kremlin-run wealth fund overseeing Sputnik V’s foreign sales....
...The three companies joining the index are Etsy, the arts and crafts marketplace, Teradyne, a manufacturer of testing equipment, and Catalent, a pharmaceutical company....
...Sanofi is one of the pharmaceutical groups working on a vaccine for Covid-19....
...After such strong reads from the first two releases (three if we count Russia’s Sputnik V), the disappointing AZN figures were perhaps bound to prompt downward pressure on the company’s shares....
...In August, Russia became the first country to approve a Covid-19 vaccine — named Sputnik V — for civilian use, but western experts cast doubt on its efficacy and safety....
...If there is a sense from this earnings season that confidence in a V-shaped recovery for profits is misplaced, then the impact will probably be hardest on companies with weak balance sheets, and on those...
...A separate group of more than 50 investors, managing more $2.5tn in assets, will next week step up the pressure by writing to more than a dozen global pharmaceutical companies....
...Art Baluszynski, head of research at Henderson Rowe, said some investors would have taken profits following the recent gains....
...Beyond these three biotechs, Crispr could end up transforming the entire pharmaceutical industry....
...Their concentrated ownership of industries such as airlines and pharmaceuticals may push up travel and drug prices, some academics argue....
...She worked as a janitorial supervisor at C&W client Lonza, a Swiss pharmaceuticals group, which has a production facility in Portsmouth, New Hampshire....
...“The healthcare sector is ripe for disruption,” said Carmel Wellso, director of research at Janus Henderson....
...He places human embryonic and pluripotent stem cells — that have the potential to grow into nearly every cell of the body — in tiny ‘U’ or ‘V’ shaped dishes in the lab to grow them into different types of...
...Pharmaceutical groups, which might see similar benefits from quantum technology in the long term, are still on the sidelines....
...Thanks to a series of court rulings since the mid-2000s, such as eBay v MercExchange in 2007, Mayo Collaborative Services v Prometheus Laboratories in 2012 and Alice Corp v CLS Bank in 2014, and the subsequent...
...the neuroscience business should not “shock investors but is likely to raise a debate over possible use of proceeds should any cash be generated and management of any earnings dilution [ie deleveraging v...
...Aberdeen Asset Management and Canada Pension Plan have also voiced opposition to the deal, as has the local company Ilsung Pharmaceuticals, which holds 2 per cent....
...(Financial Times) Roche is to buy Santaris Pharma for up to $450m in the latest piece of dealmaking by the Swiss pharmaceuticals group....
...Just one of hundreds of raids carried out worldwide through Interpol’s Operation Pangea V, nearly 200 police and regulatory agencies combined efforts to clamp down on the complex multimillion dollar international...
...John Bennett, director of European equities at Henderson, is a convert to the value case....
...Takeda Pharmaceutical plunged 3.2 per cent to Y3,290 as investors were disappointed by the drugmaker’s operating profit forecast for this fiscal year....
...beyondbrics India v China: a new race in biopharmaceuticals, beyondbrics...
...Shanghai found some support from firmer pharmaceutical stocks and the composite index ended just 0.1 per cent weaker at 2,816.69....
International Edition